We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Breast cancer prevention
This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.
The IBIS-II-O study tracks the long-term medical outcomes of 3000 + UK women who took part in the main IBIS-II clinical trials (Prevention [ISRCTN31488319], DCIS [ISRCTN37546358]) between 2004 and 2021. These studies looked at the breast cancer-preventive effect of anastrozole in women at increased risk of breast cancer. The women either took anastrozole compared with either tamoxifen (IBIS-II DCIS) or anastrozole compared with a placebo (IBIS-II Prevention) for 5 years and were then followed up for a further 5 years.
Results of IBIS-II DCIS and Prevention show that anastrozole significantly reduces the risk of developing breast cancer in these groups and that the effect continues for many years afterwards. IBIS-II-O uses data from NHS digital to track incidences of new and recurrent breast cancers, other cancers, deaths plus known side effects of anastrozole to continue to measure the long-term effects of anastrozole in these women.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. Participant death has been reported to the study during their participation in the IBIS-II Prevention and DCIS CTIMP study2. Participant has withdrawn consent to participate in IBIS-II Prevention and DCIS CTIMP studies3. Participant has withdrawn consent to digital registry flagging in the IBIS-II Prevention and DCIS CTIMP study4. Participant known to have emigrated
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Barts
Clinical Trials Unit
+44 (0)2078823517
bartsctu@qmul.ac.uk
The study is sponsored by Queen Mary University of London and funded by AstraZeneca.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
